Abstract
Summary: The lack of clinical activity from various immune-checkpoint blockade approaches in mismatch repair– proficient (MMRp) colorectal cancer has demonstrated a critical need for novel approaches. In this issue, Crisafulli and colleagues provide proof of concept for the induction of hypermutability through the use of temozolomide as a potential pathway for enabling a productive anti–PD-1 immune response in MMRp colorectal cancer.
Original language | English (US) |
---|---|
Pages (from-to) | 1612-1614 |
Number of pages | 3 |
Journal | Cancer discovery |
Volume | 12 |
Issue number | 7 |
DOIs |
|
State | Published - Jul 1 2022 |
ASJC Scopus subject areas
- Oncology